The US has moved to impose tariffs on branded drug imports, aiming to spur domestic manufacturing. But the impact may be limited because key exemptions cover companies investing in US production and imports from countries with trade agreements. Generics are unaffected, leaving Indian exporters of branded medicines needing to reassess the new compliance and pricing rules.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
